Innovent Biologics, Inc. (HKG: 1801) announced that its Phase III STAR study (NCT05972473) evaluating efdamrofusp alfa (IBI302) in Chinese patients with neovascular age‑related macular degeneration (nAMD) met its primary endpoint at 52 weeks, demonstrating non‑inferior visual acuity improvement vs. aflibercept (Eylea®) with ultra‑long 16‑week dosing intervals and a ~50% reduction in macular atrophy (MA) – a potential best‑in‑class profile for the novel VEGF/complement dual‑target therapy.
Eylea HD (8 mg aflibercept, Q12‑16W); Vabysmo (faricimab, Q16W)
IBI302 matches Q16W interval with complement differentiation
Unmet Need
Macular atrophy (affects 30‑40% of long‑term anti‑VEGF users); injection fatigue
50% MA reduction + 16‑week dosing addresses both issues
China Market Dynamics
~3 million nAMD patients; anti‑VEGF penetration <20%; growing biologics access
China‑origin asset supports pricing flexibility and NRDL inclusion
Market Impact & Outlook
nAMD Market Dynamics: Global nAMD therapeutics US$15+ billion annually; China RMB8‑10 billion with 15‑20% growth; long‑acting therapies (Eylea HD, Vabysmo) capturing 40%+ share due to reduced injection burden; IBI302’s dual‑mechanism differentiation positions for premium segment.
Innovent Ophthalmology Strategy: IBI302 lead asset in ophthalmology franchise; STAR success validates fusion protein platform; pipeline includes IBI333 (VEGF/ANG2 bispecific) for diabetic macular edema; potential for integrated retina portfolio vs. single‑asset competitors.
Regulatory & Commercial Timeline: NDA submission to NMPA Q2‑Q3 2026; potential China approval H2 2027; ex‑China rights licensing opportunity (US/EU) with estimated deal value US$500 million‑1 billion upon Phase III data disclosure; global Phase III (non‑Chinese populations) likely required for US FDA submission.
Competitive Differentiation vs. Vabysmo: Roche’s faricimab (VEGF/ANG2 bispecific) offers Q16W dosing but no complement mechanism; IBI302’s MA reduction benefit (50% vs. aflibercept) suggests superior anatomical outcome potential; head‑to‑head study vs. Vabysmo would establish market positioning.
Pricing & Access Strategy: Assuming NRDL inclusion at RMB8,000‑12,000 per injection (vs. Eylea HD ~RMB15,000); 16‑week interval reduces annual cost vs. Q8W therapies; MA reduction claim supports premium positioning and physician preference in long‑term therapy selection.
Forward‑Looking Statements This brief contains forward‑looking statements regarding regulatory submission timelines, commercialization expectations, and competitive positioning for efdamrofusp alfa (IBI302). Actual results may differ due to NMPA review outcomes, competitive dynamics with Eylea HD and Vabysmo, and manufacturing scale‑up for fusion protein production.-Fineline Info & Tech
By Fineline Cube